Servier sees one of its combo-drug (trifluridine/tipiracil) approved by the European Commission, after showing a 2 month improvement in overall survival for metastatic Colorectal cancer.
The largest private Pharma from France, Servier has well-known stake in innovative oncology therapies due to its role in the restructuring of Cellectis as a universal CAR-T Biotech – which looks extremely promising.
However, Servier has other programmes in cancer. One of those was the development of trifluridine/tipiracil, which Servier licensed from Taiho Pharmaceutical (Japan) for €113.9M upfront.
The drug was now approved by the European Comission (EC) for treatment of metastatic colorectal cancer (mCRC), after a positive recommendation by the EMA. It will be marketed under the trade name of Lonsurf.
This approval follows a phase III trial (RECOURSE) with 800 patients that had been previously treated without success (refractory).
The drug works by directly attacking the DNA of the tumor cells, reducing their growth.